Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and raises the price target from $21 to $26.
Morgan Stanley Maintains Underweight on Veracyte, Raises Price Target to $26
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.